Half a year after being spurned by the FDA and following deep layoffs, IO Biotech has decided to close its doors for good.

Ambrosia Biosciences is aiming to move the market beyond peptide-based obesity treatments and initiate a trial for its oral ...

While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to ...

U.S. venture capital firms are no longer waiting for Chinese biotech assets to surface before investing in them — they’re ...

Mantis takes disparate sources of data to make synthetic datasets that can be used to build so-called "digital twins" of the ...

Shares of IO Biotech, Inc. IOBT are plummeting Tuesday after the company announced it filed for Chapter 7 bankruptcy and will ...

Mantis Biotechnology Corp, a San Francisco-based startup, is building simulated human bodies to generate the synthetic ...

The six companies that have priced initial public offerings so far banked a median of $287.5 million, a figure far surpassing ...

Adaptive Biotechnologies, a leader in immune-driven diagnostics, reported a notable insider sale amid strong one-year stock ...

The Swiss pharma giant is betting on a next-generation allergy treatment that may prove to work faster and better than ...

CNBC's Angelica Peebles reports the latest news surrounding Big Pharma.

Discover the Latest in Research Peptides at Biotech Labz Supply Sebastopol, United States - January 3, 2026 / Biotech ...